

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF: TUDAN *ET AL*

APPLICATION No.: 10/086,177

FILING DATE: FEBRUARY 26, 2002

FOR: CXC CHEMOKINE RECEPTOR 4 AGONIST  
PEPTIDES

EXAMINER: BUNNER, BRIDGET E.

ART UNIT: 1647

CONF. No: 1250

**Information Disclosure Statement Within Three Months of  
Application Filing or Before First Action – 37 C.F.R. § 1.97(b)**

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**A. Timing of Submission**

This information disclosure is being filed within three months of the filing date of this application or date of entry into the National Stage of an International Application or before the mailing date of a first Office Action on the merits or before the mailing date of a first Office Action on the merits after the filing of a Request for Continued Examination under 37 CFR §1.114, whichever occurs last (37 CFR 1.97(b)(4)). The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

**B. Cited Information**

☒ Copies of references 1-52 are enclosed.

**C. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))**

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

**D. Fee Payment**


No fees are believed due because this Information Disclosure Statement is being filed before the mailing date of the first Office Action. However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

**E. Patent Term Adjustment (37 C.F.R. § 1.704(d))**

- ☐ The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).


Respectfully submitted,  
Perkins Coie LLP

Date: 7/24/07

  
\_\_\_\_\_  
Brian S. Boyer  
Registration No. 52,643

**Correspondence Address:**

Customer No. 22918  
Perkins Coie LLP  
P.O. Box 2168  
Menlo Park, California 94026  
(650) 838-4300



# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Form PTO-1449 (Modified)  
(Use several sheets if necessary)

## **COMPLETE IF KNOWN**

Application Number	10/086,177
Confirmation Number	1250
Filing Date	February 26, 2002
First Named Inventor	Tudan <i>et al.</i>
Group Art Unit	1647
Examiner Name	Bunner, Bridget E.
Attorney Docket No.	60568-8001.US02

## **U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		NUMBER	Kind Code (if known)			

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Foreign Patent or Application		Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	NUMBER				

## **OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	1	Barnerji, <i>et al.</i> , <i>Cell</i> , <u>33</u> :729-740 (1983).	
	2	Belperio, <i>et al.</i> , <i>J. Leukoc. Biol.</i> , <u>68</u> :1-8 (2000).	
	3	Benoist, <i>et al.</i> , <i>Nature</i> , <u>290</u> :304-310 (1981).	
	4	Bollon, <i>et al.</i> , <i>J. of Clinical Hematology and Oncology</i> , <u>10</u> :39-48 (1980).	
	5	Botstein, <i>et al.</i> , "Making Mutations in Vitro and Putting them Back Into Yeast", Dept of Biol. Massachusetts Institute of Technology, 265-274 (1982).	
	6	Broach, J.R., <u>THE MOLECULAR BIOLOGY OF THE YEAST SACCHAROMYCES</u> , 445-470 (1981).	
	7	Broach, J.R., <i>Cell</i> <u>28</u> :203-204 (1982).	
	8	Calame, <i>et al.</i> , <i>Advances in Immunology</i> , <u>43</u> :236-275 (1988).	
	9	Camper, <i>et al.</i> , <i>Genes &amp; Development</i> , <u>3</u> :537-546 (1989).	
	10	Cenatiempo, Y., <i>Biochimie</i> , <u>68</u> :505-515 (1986).	
	11	Colosimo, <i>et al.</i> , <i>BioTechniques</i> , <u>29</u> :314-331 (2000).	

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).</p>	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
Form PTO-1449 (Modified)  
(Use several sheets if necessary)



**COMPLETE IF KNOWN**


Application Number	10/086,177
Confirmation Number	1250
Filing Date	February 26, 2002
First Named Inventor	Tudan et al.
Group Art Unit	1647
Examiner Name	Bunner, Bridget E.
Attorney Docket No.	60568-8001.US02

Sheet 2 of 4

**OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	12	Daugherty, et al., <i>Chemokine Protocols</i> , <u>138</u> :129-148 (2000).	
	13	Daugherty, et al., <i>Methods in Molecular Biology</i> , <u>138</u> :129-134 (2000).	
	14	DeNardo, et al., <i>Cancer</i> , <u>94</u> :1275-1286 (2002).	
	15	Dufour, J.H., et al., <i>The Journal of Immunology</i> , <u>167</u> (7077-7083):3195-3204 (2001).	
	16	Edlund, et al., <i>Science</i> , <u>28</u> :912-916 (1985).	
	17	"Expression in <i>E. coli</i> ", <i>Methods in Enzymology</i> , <u>185</u> :119-129 (1990).	
	18	Francis, et al., <i>International Journal of Hematology</i> , <u>68</u> :1-18 (1998).	
	19	Gazitt, J. <i>Hematother. Stem Cell. Res.</i> , <u>10</u> :229-236 (2001).	
	20	Glick, et al., <i>J. of Industrial Microbiology</i> , <u>1</u> :277-282 (1987).	
	21	Glimm, et al., <i>Blood</i> , <u>99</u> (9):3454-3457 (2002).	
	22	Gold, et al., <i>Ann Rev. Microbiol.</i> , <u>35</u> :365-403 (1981).	
	23	Gottesman, S., <i>Ann. Rev. Genet.</i> , <u>18</u> :415-441 (1984).	
	24	Hamer, et al., <i>J. of Molecular and Applied Genetics</i> , <u>1</u> :273-288 (1982).	
	25	Hattori, et al., <i>Blood</i> , <u>97</u> :3354-3359 (2001).	
	26	Hébert, et al., <i>The J. of Biological Chemistry</i> , <u>266</u> (28):18989-18994 (1991).	
	27	Hunter et al., <i>Blood</i> , <u>86</u> (12):4400-4408 (1995).	
	28	John Jr., et al., <i>Reviews of Infectious Diseases</i> , <u>8</u> (5):693-704.	
	29	Johnston, et al., <i>Proc. Natl. Acad. Sci. USA</i> <u>79</u> :6971-6975 (1982).	

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).</p>	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Form PTO-1449 (Modified) (Use several sheets if necessary)						<b>COMPLETE IF KNOWN</b>	
				Application Number		10/086,177	
				Confirmation Number		1250	
				Filing Date		February 26, 2002	
				First Named Inventor		Tudan <i>et al.</i>	
				Group Art Unit		1647	
Examiner Name		Bunner, Bridget E.		Attorney Docket No.		60568-8001.US02	
Sheet	3	of	4				

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.		
	30	Kaltsas, <i>et al.</i> , <i>Ann. Oncol.</i> , <u>12</u> (Supp. 2)S47-50 (2001).		
	31	Kessel, <i>et al.</i> , <i>Science</i> , <u>249</u> :374-379 (1990).		
	32	Kieseier, <i>et al.</i> , <i>Brain</i> , <u>125</u> :823-824 (2002).		
	33	Lane, <i>et al.</i> , <i>Blood</i> , <u>96</u> :4152-4159 (2000).		
	34	Lejeune, <i>et al.</i> , <i>Cancer Immunol. Immunother.</i> , <u>38</u> :167-170 (1994).		
	35	Mach, <i>et al.</i> , <i>Curr. Opin. Immunol.</i> , <u>12</u> :571-575 (2000).		
	36	McKnight, S.L., <i>Cell</i> , <u>31</u> :355-365 (1982).		
	37	McLaughlin, S., <i>et al.</i> , <i>J. Virology</i> , <u>62</u> (6):1963-1973 (1988).		
	38	Miller, <i>et al.</i> , "An Insect Baculovirus Host-Vector System for High-Level Expression of Foreign Genes," 277-297 (1986).		
	39	Miller, <i>et al.</i> , <i>J. Immunol.</i> <u>143</u> (9):2907-2916, (1989).		
	40	Moss, J., <i>American Chem. Soc.</i> <u>18</u> :423-448, (1995).		
	41	Nagasawa, <i>Int. J. Hematol.</i> <u>72</u> :408-411, (2000).		
	42	Nomura, <i>et al.</i> , <i>Int. J. Cancer</i> , <u>91</u> :597-606 (2001).		
	43	Pinkert, <i>et al.</i> , <i>Genes &amp; Development</i> , <u>1</u> :268-276 (1987).		
	44	Ponath, <i>et al.</i> , <i>Methods in Molecular Biology</i> , <u>138</u> :113-120 (2000).		
	45	Queen, <i>et al.</i> , <i>Cell</i> , <u>33</u> :741-748 (1983).		
	46	Rubin, G.M., <i>Science</i> , <u>240</u> :1453-1459 (1988).		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	

<p align="center"><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p align="center">Form PTO-1449 (Modified)</p> <p align="center">(Use several sheets if necessary)</p>				<b>COMPLETE IF KNOWN</b>	
				Application Number	10/086,177
				Confirmation Number	1250
				Filing Date	February 26, 2002
				First Named Inventor	Tudan <i>et al.</i>
				Group Art Unit	1647
Examiner Name	Bunner, Bridget E.				
Attorney Docket No.	60568-8001.US02				
Sheet	4	of	4		

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.		
	47	Schwarz, <i>et al.</i> , <i>Nat. Rev. Drug Discov.</i> , <u>1</u> :347-358 (2002).		
	48	Silver, <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , <u>81</u> :5951-5955 (1984).		
	49	Smith, <i>et al.</i> , <i>Gene</i> , <u>67</u> :31-40 (1988).		
	50	Wada, <i>et al.</i> , <i>Nucleic Acids Research</i> , <u>20</u> :2111-2118 (1992).		
	51	Wang, W., <i>et al.</i> , <i>The Journal of Biological Chemistry</i> , <u>275</u> (29):22313-22323 (2000).		
	52	Winoto, <i>et al.</i> , <i>The EMBO J.</i> , <u>8</u> (3):729-733 (1989).		

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).</p>	